Magellan Health Insights
  • Home
  • About
  • Resources
  • Voices
  • Contact

Magellan’s Collaboration with Click Therapeutics Expanded to Develop FDA-Cleared Therapeutic Apps

by Magellan Health Insights August 18, 2017Magellan Health, Telehealth

Over the past decade, technology has become enmeshed in our lives. From the ubiquitous smartphones we all carry, to connected houses, cars, cameras and more — it seems like just about every object we come into contact with is gaining new capabilities from being connected to the cloud. At Magellan Health, we feel strongly that an individual’s health should benefit from these technological advancements, too.

We are excited to announce that Magellan is expanding its existing collaboration with Click Therapeutics to create Food and Drug Administration (FDA) cleared therapeutic apps.

Digital health apps are an area that Magellan continues to lead in research and development. Magellan’s Director of Innovation, Brian Keenaghan, recently shared his experience building apps to promote healthy vibrant lives.

 FDA Clearance for Digital Therapeutics

Click will leverage Magellan’s portfolio of software programs, associated intellectual property, and data to create mobile apps for people challenged by conditions such as insomnia, substance abuse, depression and anxiety, and apply for FDA clearance for such apps on the basis of valid scientific evidence supporting the safety and effectiveness of the software. This augments Magellan’s work to provide broad-based, digital and data-driven programs for primary care and specialty care providers.

Magellan Health and Click Therapeutics: Rethinking Healthcare

Last year, Magellan launched a tobacco cessation program with Click Therapeutics leveraging Magellan’s clinical coaching and pharmacy benefit management (PBM) capabilities with Click’s technology and machine learning platform, including the mobile application, CLICKOTINE®, to create an all-in-one solution.

Magellan’s CCBT modules have undergone numerous clinical trials in which they have matched, and in some instances exceeded, those reached by conventionally delivered cognitive behavioral therapy. In addition, Cobalt has received the highest rating from the Substance Abuse and Mental Health Administration’s (SAMHSA) National Registry of Evidence-based Programs and Practices (NREPP).

You can learn more about Magellan’s Cobalt CCBT capabilities here.

Share on FacebookShare on TwitterShare on Linkedin
Tags: CCBT, Clickotine, Cobalt, Magellan, Magellan Health, Magellan RX, National Registry of Evidence-Based Programs and Practices, NREPP, Pharmacy Benefit Management, SAMHSA, Substance Abuse Mental Health Services Administration
Magellan Health Insights
Previous post Reaffirming Our Values and Standing Tall Next post Nearly half of patients who stop taking opioids for six months resume use later

Related Articles

blogpost_hands

Care alongside Care: Treating Comorbid Medical and Behavioral Conditions

by Caroline Carney
April 14, 2017
Paying-Bills-with-a-Magellan-Blue-Card

Sanity Savers: Tips for managing holiday stress

by Magellan Health Insights
December 15, 2017
I am a woman in technology, what is your super power?

I am a woman in technology, what is your super power?

by Gabi Vandermark
May 16, 2018

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Magellan Health Logo

To learn more about how Magellan can support your organization, please visit MagellanHealth.com.

Topic suggestions or questions?
Send us your ideas at

Connect with us:

Trending Topics

  • A Present Day Look at PTSD
  • Medicine Cabinet Minefield: How old prescriptions drugs are fueling an opioid addiction crisis
  • The Trends and Complexities of Provider-Administered Drugs

Categories

Stay in the Know

Get the latest news and trending insights sent straight to your inbox.


HomeAboutResourcesVoicesContact
© 1999-2016 Magellan Health, Inc. All Rights Reserved.